97 related articles for article (PubMed ID: 6103646)
21. Agonist interactions with dopamine receptors: focus on radioligand-binding studies.
Creese I; Sibley DR; Leff SE
Fed Proc; 1984 Oct; 43(13):2779-84. PubMed ID: 6383871
[TBL] [Abstract][Full Text] [Related]
22. Effects of drugs and lesions on dopamine-stimulated adenylate cyclase: evidence for different classes of dopamine receptors.
Katzman R; Makman MH; Ahn HS; Mishra RK; Gardner E
Trans Am Neurol Assoc; 1977; 102():76-9. PubMed ID: 98893
[No Abstract] [Full Text] [Related]
23. Similarities and dissimilarities between dopamine and neuroleptic receptors: further evidence for type 1 and type 2 dopamine receptors in the CNS.
Spano PF; Memo M; Govoni S; Trabucchi M
Adv Biochem Psychopharmacol; 1980; 24():113-21. PubMed ID: 6105769
[No Abstract] [Full Text] [Related]
24. How do antipsychotic drugs work?
Iversen LL
Neurosci Res Program Bull; 1975 Aug; 13 Suppl():29-51. PubMed ID: 241033
[No Abstract] [Full Text] [Related]
25. Further characterization of structural requirements for agonists at the striatal dopamine D-1 receptor. Studies with a series of monohydroxyaminotetralins on dopamine-sensitive adenylate cyclase and a comparison with dopamine receptor binding.
Seiler MP; Markstein R
Mol Pharmacol; 1982 Sep; 22(2):281-9. PubMed ID: 7144729
[No Abstract] [Full Text] [Related]
26. Identification and localization of the recognition binding subunit of the D1 dopamine receptor.
Tanaka C; Kuno T; Mita T; Ishibe T
Adv Biochem Psychopharmacol; 1983; 36():135-45. PubMed ID: 6858751
[No Abstract] [Full Text] [Related]
27. Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.
Bacopoulos NG
J Pharmacol Exp Ther; 1981 Dec; 219(3):708-14. PubMed ID: 6170752
[TBL] [Abstract][Full Text] [Related]
28. Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO].
Martin GE; Williams M; Pettibone DJ; Yarbrough GG; Clineschmidt BV; Jones JH
J Pharmacol Exp Ther; 1984 Sep; 230(3):569-76. PubMed ID: 6433000
[TBL] [Abstract][Full Text] [Related]
29. Receptors acting through adenylate cyclase in the CNS.
Wollemann M
Acta Physiol Acad Sci Hung; 1980; 55(4):299-304. PubMed ID: 6258390
[TBL] [Abstract][Full Text] [Related]
30. [Current theories on the role of dopamine in the mechanism of action of neuroleptic drugs].
Płaźnik A; Kostowski W
Psychiatr Pol; 1984; 18(1):39-47. PubMed ID: 6146150
[No Abstract] [Full Text] [Related]
31. Dopamine receptors and schizophrenia: the neuroleptic drug problem.
Reynolds GP; Riederer P; Jellinger K; Gabriel E
Neuropharmacology; 1981 Dec; 20(12B):1319-20. PubMed ID: 6119642
[No Abstract] [Full Text] [Related]
32. Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary.
Enjalbert A; Bockaert J
Mol Pharmacol; 1983 May; 23(3):576-84. PubMed ID: 6306429
[TBL] [Abstract][Full Text] [Related]
33. Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
Hornykiewicz O
Annu Rev Pharmacol Toxicol; 1977; 17():545-59. PubMed ID: 17361
[No Abstract] [Full Text] [Related]
34. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
[TBL] [Abstract][Full Text] [Related]
35. Evidence that the D-2 dopamine receptor in the intermediate lobe of the rat pituitary gland is associated with an inhibitory guanyl nucleotide component.
Cote TE; Frey EA; Grewe CW; Kebabian JW
J Neural Transm Suppl; 1983; 18():139-47. PubMed ID: 6308147
[TBL] [Abstract][Full Text] [Related]
36. Dopamine receptor of the porcine anterior pituitary gland. Evidence for two affinity states discriminated by both agonists and antagonists.
De Lean A; Kilpatrick BF; Caron MG
Mol Pharmacol; 1982 Sep; 22(2):290-7. PubMed ID: 7144730
[No Abstract] [Full Text] [Related]
37. Abnormal neuroleptic/dopamine receptors in schizophrenia.
Lee T; Seeman P
Adv Biochem Psychopharmacol; 1980; 21():435-42. PubMed ID: 6103653
[TBL] [Abstract][Full Text] [Related]
38. Neuroleptic activity of the 5-aryltetrahydro-gamma-carboline series. Conformational requirements for interaction with central dopamine receptors.
Harbert CA; Plattner JJ; Welch WM; Weissman A; Koe BK
Mol Pharmacol; 1980 Jan; 17(1):38-42. PubMed ID: 6104285
[No Abstract] [Full Text] [Related]
39. Pharmacological characterization of the dopamine-mediated accumulation of cyclic AMP in intact retina of rabbit.
Schorderet M
Life Sci; 1977 May; 20(10):1741-7. PubMed ID: 17798
[No Abstract] [Full Text] [Related]
40. In vivo blockade of dopaminergic receptors from different rat brain regions by classical and atypical neuroleptics.
Le Fur G; Guilloux F; Uzan A
Biochem Pharmacol; 1980 Feb; 29(3):267-70. PubMed ID: 6102466
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
